Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: Prostatic Neoplasms trials

The registry lists 73 Prostatic Neoplasms studies with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor. 11 are open to participants now and 35 have results posted.

Early Phase 1 5Phase 1 20Phase 2 35Phase 3 1No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Physician- and Patient-based Barriers to NGS TestingRecruitingNCT07209176Not applicable
• Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingNCT07142551Phase 2
• The COSMYC Trial (COmbined Suppression of MYC)RecruitingNCT06922318Phase 2
• Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate CancerAvailableNCT06836648
• 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate CancerRecruitingNCT06826924Not applicable
• Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerRecruitingNCT06616597Phase 2
• SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment OptimizationRecruitingNCT06389097
• Exercise in Prostate CancerRecruitingNCT06165302Not applicable
• Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer PatientsRecruitingNCT06138067Not applicable
• Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06059118Phase 2
• Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CTRecruitingNCT03861676Early Phase 1
• Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerTerminatedNCT05501548Phase 2Results posted
• Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT05081193Phase 2Results posted
• RAdium-223 and SABR Versus SABR for Oligometastatic Prostate CancersCompletedNCT04037358Phase 2Results posted
• Nivolumab in Biochemically Recurrent dMMR Prostate CancerCompletedNCT04019964Phase 2Results posted
• Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate CancerTerminatedNCT03886493Phase 2Results posted
• COMbination of Bipolar Androgen Therapy and NivolumabCompletedNCT03554317Phase 2Results posted
• Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen SuppressionCompletedNCT03507608Early Phase 1Results posted
• Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsCompletedNCT03413995Phase 2Results posted
• A Study of Definitive Therapy to Treat Prostate Cancer After ProstatectomyCompletedNCT03043807Phase 2Results posted
• Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate CancerTerminatedNCT02995330Phase 1Results posted
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerActive, not recruitingNCT02923180Phase 2Results posted
• A Study of Definitive Therapy to Treat Prostate CancerCompletedNCT02716974Phase 2Results posted
• Stereotactic Body Radiation for Prostate OligometastasesCompletedNCT02680587Phase 2Results posted
• Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7CompletedNCT02601014Phase 2Results posted
• Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate CancerTerminatedNCT02516670Phase 2Results posted
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and DocetaxelTerminatedNCT02491411Not applicableResults posted
• Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate CancerCompletedNCT02489357Not applicableResults posted
• Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCCompletedNCT02463799Phase 2Results posted
• Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistanceCompletedNCT02286921Phase 2Results posted
• A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor BiopsyCompletedNCT02115828Early Phase 1Results posted
• A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate CancerCompletedNCT02111187Phase 1Results posted
• RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)CompletedNCT02090114Phase 2Results posted
• Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate CancerCompletedNCT01815515Phase 1/2Results posted
• Bipolar Androgen-based Therapy for Prostate Cancer (BAT)CompletedNCT01750398Phase 2Results posted
• A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate CancerCompletedNCT01696877Phase 1/2Results posted
• Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate CancerCompletedNCT01496157Phase 1/2Results posted
• Pre-Prostatectomy Lovastatin on Prostate CancerTerminatedNCT01478828Not applicableResults posted
• Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate CancerCompletedNCT01317199Phase 1/2Results posted
• Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)CompletedNCT01118741Not applicableResults posted
• A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate CancerCompletedNCT01084759Not applicableResults posted
• Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the ProstateCompletedNCT00809991Phase 2Results posted
• Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate CancerTerminatedNCT00670046Phase 2Results posted
• Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate BrachytherapyCompletedNCT00381966Not applicableResults posted
• Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate CancerCompletedNCT00348595Phase 1/2Results posted
• Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate CancerCompletedNCT00311623Phase 1/2Results posted
• Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerActive, not recruitingNCT06014255Phase 2
• A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate CancerWithdrawnNCT05574712Phase 2
• [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate CancerTerminatedNCT04528199Phase 1
• EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer ProgressionCompletedNCT04266431Not applicable
• Biopsy Collection for Men Undergoing Brachytherapy for Prostate CancerWithdrawnNCT04243473
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerWithdrawnNCT03800784Phase 2/3
• Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate CancerCompletedNCT03793543Phase 1
• Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to TherapyTerminatedNCT03619655Phase 1
• Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.CompletedNCT03497377Phase 1
• Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate CancerActive, not recruitingNCT03471650Phase 2
• Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, ClarithromycinTerminatedNCT03043989Phase 1
• Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate CancerCompletedNCT02856100
• Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate CancerCompletedNCT02825875
• Cancer DNA Detection in Blood and UrineCompletedNCT02657863
• Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate CancerTerminatedNCT02478125Phase 1
• Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT02452008Phase 2
• Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate CancerCompletedNCT02420977Early Phase 1
• A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerWithdrawnNCT02396368Phase 1
• Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate CancerCompletedNCT02151760Phase 1
• Robot-Assisted MRI-Guided Prostate BiopsyCompletedNCT02080052Not applicable
• Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate CancerTerminatedNCT01983709Phase 1
• MRI for Assessing Prostate Cancer ResponseActive, not recruitingNCT01607008Not applicable
• Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate CancerCompletedNCT01417182Phase 1
• Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate CancerCompletedNCT01359189Phase 1
• Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate CancerCompletedNCT00559429Phase 1
• Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
• Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate CancerCompletedNCT00022399Phase 2